Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid CancerBusiness Wire • 03/25/22
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver CancerBusiness Wire • 03/14/22
Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/17/22
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdateBusiness Wire • 02/17/22
Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer TrialBenzinga • 02/15/22
Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022Business Wire • 02/03/22
Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022Business Wire • 02/02/22
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022Business Wire • 01/18/22
Exelixis (EXEL) Announces Preliminary Q4 Results, Issues View (Revised)Zacks Investment Research • 01/11/22
Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022Business Wire • 01/09/22
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue FactorBusiness Wire • 01/06/22